Piper Jaffray Starts Flex Pharma (FLKS) at Overweight; Sees ~70% Upside
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
JMP Securities Starts Flex Pharma (FLKS) at Market Outperform
February 23, 2015 7:34 AM ESTJMP Securities initiated coverage on Flex Pharma (NASDAQ: FLKS) with a Market Outperform rating and a price target of $30.00.
For an analyst ratings summary and ratings history on Flex Pharma click here. For more ratings news on Flex Pharma click here.
Shares of Flex Pharma closed at $14.71 yesterday.
... MoreCantor Fitzgerald Starts Flex Pharma (FLKS) at Buy
February 23, 2015 7:34 AM ESTCantor Fitzgerald initiated coverage on Flex Pharma (NASDAQ: FLKS) with a Buy rating and a price target of $22.00.
For an analyst ratings summary and ratings history on Flex Pharma click here. For more ratings news on Flex Pharma click here.
Shares of Flex Pharma closed at $14.71 yesterday.
... MoreRoth Capital Starts Flex Pharma (FLKS) at Buy
February 23, 2015 7:33 AM ESTRoth Capital initiated coverage on Flex Pharma (NASDAQ: FLKS) with a Buy rating and a price target of $27.00.
For an analyst ratings summary and ratings history on Flex Pharma click here. For more ratings news on Flex Pharma click here.
Shares of Flex Pharma closed at $14.71 yesterday.
... MoreJefferies Starts Flex Pharma (FLKS) at Buy
February 23, 2015 7:15 AM ESTJefferies initiates coverage on Flex Pharma (NASDAQ: FLKS) with a Buy rating and a price target of $25.00.
Analyst Ryan Martins comments, "FLKS' proprietary formulation of transient receptor potential (TRP) ion channel activators is well positioned to address muscle cramps and other neuromuscular... More
